ANTIBODIES

Contributor Information
- Institute University of Tartu
Tool Details
- Tool name: Anti-human Neuropilin-1 b1b2 [clone 1A4; mAb1]
- Alternate names: 1A4, mAB1 (mAB1 in studies published in Science)
- Tool type: Antibodies
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: IHC ; IF ; WB
- Description: Monoclonal antibody raised against human NRP-1 b1b2 domain, clone 1A4 (mAB1 in studies published in Science). Partially blocking binding of CendR peptides to b1 domain of NRP-1. In recent years the relevance of CendR pathway for cellular uptake of biological nanoparticles ÄËĂÂĂÂ viruses - has been demonstrated in several independent studies. A direct role of Neuropilin (NRP) in virus entry has been demonstrated for three viruses, the retrovirus Human T-cell lymphotropic virus type 1 (HTLV-1) and the herpes viruses EBV and CMV5-8. In the case of CMV, NRP-2 acts as a receptor only for specific cell types, while in fibroblasts the virus uses a different molecule for entry. Viruses that display CendR peptides on their surface are expected to bind a specific CendR binding pocket on the extracellular domain of NRP. Ample evidence obtained with synthetic and phage-displayed CendR peptides shows that they bind to conserved binding pocket in b1 domain of NRP-1. The inventors have developed a monoclonal antibody that specifically interacts with the CendR binding pocket of the b1 domain of Neuropilin-1 and blocks binding of CendR peptides. This monoclonal antibody has potential applications in the research of SARS-CoV2 in that the antibody is capable to reduce/block the internalisation of SARS-CoV2 into cells, thus to stop viral replication.
- Immunogen: See Xbio/UOT/V/ b1b2wt and Xbio/UOT/V/ b1b2tm
- Research area: Microbiology
- Myeloma used: P3X63Ag8.653
- For Research Use Only
Target Details
- Target: human Neuropillin-1 b1b2 domain
- Target background: Monoclonal antibody raised against human NRP-1 b1b2 domain, clone 1A4 (mAB1 in studies published in Science). Partially blocking binding of CendR peptides to b1 domain of NRP-1. In recent years the relevance of CendR pathway for cellular uptake of biological nanoparticles ÄËĂÂĂÂ viruses - has been demonstrated in several independent studies. A direct role of Neuropilin (NRP) in virus entry has been demonstrated for three viruses, the retrovirus Human T-cell lymphotropic virus type 1 (HTLV-1) and the herpes viruses EBV and CMV5-8. In the case of CMV, NRP-2 acts as a receptor only for specific cell types, while in fibroblasts the virus uses a different molecule for entry. Viruses that display CendR peptides on their surface are expected to bind a specific CendR binding pocket on the extracellular domain of NRP. Ample evidence obtained with synthetic and phage-displayed CendR peptides shows that they bind to conserved binding pocket in b1 domain of NRP-1. The inventors have developed a monoclonal antibody that specifically interacts with the CendR binding pocket of the b1 domain of Neuropilin-1 and blocks binding of CendR peptides. This monoclonal antibody has potential applications in the research of SARS-CoV2 in that the antibody is capable to reduce/block the internalisation of SARS-CoV2 into cells, thus to stop viral replication.
Application Details
- Application: IHC ; IF ; WB
Handling
- Format: Liquid
- Shipping conditions: Shipping at 4ðC
Related Tools
References
- • Cantuti-Castelvetri et al. 2020. Science. 370(6518):856-860. PMID: 33082293.
- • Daly et al. 2020. Science. 370(6518):861-865. PMID: 33082294.